ImmunityBio, Inc.
IBRX
$2.33
-$0.05-2.10%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 28.61% | -119.14% | 30.99% | 36.29% | -0.34% |
Total Depreciation and Amortization | 1.33% | -7.47% | -7.12% | 1.11% | -3.27% |
Total Amortization of Deferred Charges | -- | -- | -19.23% | 6.29% | 5.10% |
Total Other Non-Cash Items | -76.62% | 355.08% | -78.07% | -173.26% | -11.00% |
Change in Net Operating Assets | 74.79% | -103.24% | -7.88% | -287.40% | 237.76% |
Cash from Operations | 7.17% | -0.89% | 13.79% | 1.58% | 6.20% |
Capital Expenditure | 3.57% | 46.90% | 24.39% | -285.64% | 42.59% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -386.88% | -56.05% | -82.39% | 233.60% | -47.74% |
Cash from Investing | -490.94% | -58.01% | -84.88% | 226.30% | -44.55% |
Total Debt Issued | -- | -- | -100.00% | -- | -- |
Total Debt Repaid | -- | -- | 100.00% | -4.76% | 0.00% |
Issuance of Common Stock | 78,598.18% | -99.80% | 577.43% | -69.68% | 271.58% |
Repurchase of Common Stock | 73.21% | -49.69% | -168.56% | 39.72% | 87.17% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -200.00% | 3,232,066.67% |
Cash from Financing | 17,697.76% | -100.92% | 586.23% | -89.53% | 1,356.18% |
Foreign Exchange rate Adjustments | 860.00% | -42.86% | -163.64% | -8.33% | 130.77% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 193.03% | -361.82% | 274.29% | -518.83% | 97.79% |